{"nctId":"NCT00628589","briefTitle":"Staccato Loxapine in Agitated Patients With Schizophrenia","startDateStruct":{"date":"2008-02"},"conditions":["Patients With Schizophrenia and Acute Agitation"],"count":344,"armGroups":[{"label":"Inhaled Loxapine 5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Inhaled loxapine 5 mg"]},{"label":"Inhaled Loxapine 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Inhaled loxapine 10 mg"]},{"label":"Inhaled placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Inhaled placebo"]}],"interventions":[{"name":"Inhaled loxapine 5 mg","otherNames":["ADASUVE"]},{"name":"Inhaled loxapine 10 mg","otherNames":["ADASUVE"]},{"name":"Inhaled placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female adult patients with schizophrenia and acute agitation\n\nExclusion Criteria:\n\n* Agitation caused primarily by acute intoxication\n* History of drug or alcohol dependence\n* Treatment with benzodiazepines or other hypnotics within 4 hours prior to study drug administration","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in PANSS-EC From Baseline","description":"The Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"4.92"},{"groupId":"OG001","value":"-8.1","spread":"5.17"},{"groupId":"OG002","value":"-8.6","spread":"4.37"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression-Improvement (CGI-I) Score","description":"Clinical Global Impression- Improvement (CGI-I) scores ranged from 1 to 7: 0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"1.11"},{"groupId":"OG001","value":"2.3","spread":"1.24"},{"groupId":"OG002","value":"2.1","spread":"1.00"}]}]}]},{"type":"SECONDARY","title":"CGI-I Responders","description":"Frequency of response based on the CGI-I (defined as achieving a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"75","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":115},"commonTop":["Sedation","Dizziness","Dysgeusia","Headache","Nausea"]}}}